Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

RESIGNATION OF JOINT COMPANY SECRETARY AND

CHANGE OF AUTHORISED REPRESENTATIVE

The board of directors (the "**Board**") of Ascletis Pharma Inc. (the "**Company**") announces that Mr. Jianjiong WANG ("**Mr. Wang**") has resigned as a joint company secretary of the Company and ceased to act as an authorised representative of the Company (the "Authorised Representative") for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, both with effect from March 13, 2019.

Mr. Wang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

Following the resignation of Mr. Wang, Mr. Lok Kwan YIM, the other joint company secretary of the Company who meets the requirements of a company secretary under Rule 3.28 of the Listing Rules, will remain in office and act as the sole company secretary of the Company.

The Board further announces that Mrs. Judy Hejingdao WU, an executive director of the Company, has been appointed as an Authorised Representative of the Company, with effect from March 13, 2019.

The Board would like to express its gratitude to Mr. Wang for his contributions to the Company during his tenure of service.

> By order of the Board Ascletis Pharma Inc. 歌禮製藥有限公司 Jinzi Jason WU Chairman

Hangzhou, the People's Republic of China March 13, 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.